Evan David Seigerman
Stock Analyst at BMO Capital
(3.34)
# 1,014
Out of 4,761 analysts
35
Total ratings
37.5%
Success rate
9.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $89.50 | +7.26% | 4 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $208 → $215 | $202.08 | +6.39% | 7 | Feb 3, 2025 | |
| REPL Replimune Group | Maintains: Outperform | $18 → $27 | $13.98 | +93.13% | 3 | Jan 22, 2025 | |
| NVO Novo Nordisk | Maintains: Outperform | $156 → $105 | $88.08 | +19.21% | 5 | Dec 23, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,300 → $1,190 | $700.33 | +69.92% | 5 | Nov 1, 2024 | |
| GPCR Structure Therapeutics | Maintains: Outperform | $83 → $100 | $23.77 | +320.79% | 2 | Jun 7, 2024 | |
| AMGN Amgen | Maintains: Outperform | $336 → $355 | $303.01 | +17.16% | 3 | May 3, 2024 | |
| PFE Pfizer | Reiterates: Outperform | $33 → $36 | $26.30 | +36.88% | 4 | May 2, 2024 | |
| CADL Candel Therapeutics | Maintains: Outperform | $9 → $3 | $11.63 | -74.20% | 1 | May 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $369 → $396 | $873.68 | -54.67% | 1 | Sep 6, 2022 |
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $89.50
Upside: +7.26%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208 → $215
Current: $202.08
Upside: +6.39%
Replimune Group
Jan 22, 2025
Maintains: Outperform
Price Target: $18 → $27
Current: $13.98
Upside: +93.13%
Novo Nordisk
Dec 23, 2024
Maintains: Outperform
Price Target: $156 → $105
Current: $88.08
Upside: +19.21%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $1,300 → $1,190
Current: $700.33
Upside: +69.92%
Structure Therapeutics
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $23.77
Upside: +320.79%
Amgen
May 3, 2024
Maintains: Outperform
Price Target: $336 → $355
Current: $303.01
Upside: +17.16%
Pfizer
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $26.30
Upside: +36.88%
Candel Therapeutics
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $11.63
Upside: -74.20%
Eli Lilly and Company
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $873.68
Upside: -54.67%